NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT02489903 2025-03-17RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)EpicentRx, Inc.Phase 2 Completed139 enrolled 14 charts
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled